WaveMan
WaveMan · Company
BIOX · Bioceres Crop Solutions Corp.
> Search tickers & screens ⌘K
LIVE
← All companies

BIOX Bioceres Crop Solutions (BIOX) Insider Trading, Ownership & Congress Trades

Materials · Agricultural chemicals · CIK 0001769484
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
9
13F, latest reported quarter

Bioceres Crop Solutions insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Bioceres Crop Solutions Corp. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Foreign private issuer: its insiders are exempt from SEC Form 4 and report in the home market, so their buys and sells do not appear here.

Insider
Filed
Shares
Value
Since filing

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
9 funds bought in last quarter
below 91% of Materials
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
2.0% of the float short (float per yahoo 2026-10-26) · 3.2 days to cover · settled 2026-09-30
below 77% of Materials
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BIOX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-88.1%12M
-90%-59%-29%+2%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BIOX: institutional holders (13F)

13F holdings, latest reported quarter
Solel Partners LP
4,579,364 sh
$1.6M
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.
1,406,223 sh
$492.3K
Long Focus Capital Management, LLC
829,748 sh
$290.5K
ARDSLEY ADVISORY PARTNERS LP
475,000 sh
$166.3K
UBS Group AG
408,276 sh
$142.9K

Congress trades in BIOX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BIOX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

BIOX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco NASDAQ Future Gen 200 ETF
$61.2K position · as of 2026-05-31
0.3%
Global X MSCI Argentina ETF
$488.5K position · as of 2026-07-31
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 9 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
JELDLEGHWMSAVYSXTENTGREXGEVOCMTKOPNKEBNET

BIOX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
no equity line filed
Return on assets
-34.8%
TTM net income over average of 2024-12-31 and 2025-12-31
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
n/a
no debt line filed
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-062024-062023-062022-06
Gross profit$131.7M$186.6M$184.6M$126.5M
Net income-$58.8M$7.3M$20.2M-$3.9M
SEC XBRL, fiscal years, as known on 2026-10-28

BIOX Stock Sonar score 2/7 axes

Find similar shapesCompare
Institutional and government
9
Inputs
  • Funds adding, latest quarter9 · 9 pct, sector of 118
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
80
Inputs
  • Short interest, % of float+2.0% · 80 pct, sector of 143
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
5 not measured: Profitability, Financial health, Growth, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 1 present: fewer than four consecutive quarters of operating income; no equity line filed
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies